Stockreport

Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc.  (EQ) 
Last equillium, inc. earnings: 3/26 04:07 pm Check Earnings Report
PDF LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe auto [Read more]